Irvine, CA (PRWEB)
July 14, 2015
Proove Biosciences, a commercial and research leader in Personalized Medicine, recently presented data on three ground-breaking scientific studies at the Neurological Disorders Summit in San Francisco, CA. The Neurological Disorders Summit took place on July 6th, 2015 and concluded on July 8th, 2015. The event was designed to be an all-encompassing forum for health professionals, researchers, neurologists, clinicians, and to engage and exchange new ideas in neurologic research and development. Proove Biosciences participated through the presentation of three new studies: 1) Genetics and Migraine: Study on the Relationship Between COMT and Migraine, 2) Genetics and Fibromyalgia: Study on the Relationship Between HTR2A and Fibromyalgia, and 3) Genetics and Insomnia: Study on the Role of DAT1 in Risk of Insomnia.
Migraine affects approximately 1 billion people worldwide, with considerable debate surrounding the environmental and genetic causes of the disorder. The Genetics and Migraine: Study on the Relationship Between COMT and Migraine aimed to investigate the role of genetic variations in relation to susceptibility to migraine. By analyzing the DNA of a group of patients diagnosed with migraine and comparing the results to the DNA of a “control” group, Proove Biosciences researchers found that a Val158Met genetic variation in the Catechol-O-Methyltransferase gene, which has been shown to result in increased dopamine levels, may play a significant role in the genetic predisposition to migraine.
The second study, Genetics and Fibromyalgia: Study on the Relationship between HTR2A and Fibromyalgia, investigated the genetic underpinning of a diagnosis of Fibromyalgia, a disorder of unknown cause with symptoms ranging from chronic widespread pain, increased pain perception, and fatigue. By collating and analyzing the genetic information of 185 patients from across 59 clinical research sites, Proove Biosciences researchers found that a genetic variant in the serotonin receptor was associated with Fibromyalgia, suggesting that medications that affect serotonin levels may help to improve the symptoms of a subgroup of patients suffering from Fibromyalgia.
With 1 in 3 adults suffering from some form of insomnia in their lifetime, insomnia is one of the most common sleep disorder. The Genetics and Insomnia: Study on the Role of DAT1 in Risk of Insomnia investigated the influence of genetics on insomnia to better characterize the disorder and provide objective information for more effective treatment. Proove Biosciences researchers found that genetic variations in the dopamine transporter gene DAT1, which regulates dopaminergic neurotransmission relevant to arousal and sleep/wake cycles, are associated with insomnia.
“With the ability to capture and analyze vast amounts of medical and genetic data together, Proove Biosciences has the unique ability to conduct primary research in natural, clinical settings,” stated Svetlana Kantorovich, Proove Biosciences’ Director of Clinical and Scientific Affairs “This information serves to both identify risk factors for disorders and generate hypotheses about patient stratification for more effective treatment.”